SCM
STRO icon

Silverarc Capital Management’s Sutro Biopharma STRO Stock Holding History

Silverarc Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,500
Closed -$4.02M – 101
2020
Q4 		$4.02M Buy
+18,500
New +$3.06M 2.33% 15

Other funds holding STRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Silverarc Capital Management's STRO Position: Q1 2021 in Review

Silverarc Capital Management sold out of Sutro Biopharma (STRO) in Q1 2021, closing a stake of 18,500 shares — an estimated $4.02M sold.

Silverarc Capital Management first reported a position in STRO in Q4 2020 and held it in 1 quarter. The position peaked at $4.02M in Q4 2020. 138 funds tracked by Wall St. Rank hold STRO as of Q1 2021.

  • Silverarc Capital Management reported no remaining Sutro Biopharma position as of Q1 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 18,500 Sutro Biopharma shares in Q1 2021, an estimated $4.02M.
  • Silverarc Capital Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 1 quarter.
  • Silverarc Capital Management's Sutro Biopharma position peaked at $4.02M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2021.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.